Harbor Capital Advisors, Inc. Replimune Group, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$6.87 - $9.31 $64,605 - $87,551	9,404 Added 29.1%	41,715 $341,000
Q4 2023 Jan 08, 2024	BUY	$6.75 - $16.18 $12,447 - $29,835	1,844 Added 6.05%	32,311 $272,000
Q3 2023 Oct 20, 2023	BUY	$15.96 - $22.18 $74,996 - $104,223	4,699 Added 18.24%	30,467 $521,000
Q2 2023 Jul 11, 2023	BUY	$15.65 - $24.1 $36,558 - $56,297	2,336 Added 9.97%	25,768 $598,000
Q1 2023 Apr 26, 2023	SELL	$17.48 - $29.09 $63,434 - $105,567	-3,629 Reduced 13.41%	23,432 $413,000
Q4 2022 Jan 20, 2023	SELL	$17.09 - $27.91 $9,963 - $16,271	-583 Reduced 2.11%	27,061 $0
Q3 2022 Oct 28, 2022	SELL	$15.6 - $21.15 $47,595 - $64,528	-3,051 Reduced 9.94%	27,644 $477,000
Q2 2022 Jul 26, 2022	BUY	$13.32 - $19.98 $6,833 - $10,249	513 Added 1.7%	30,695 $537,000
Q1 2022 Apr 28, 2022	SELL	$15.24 - $29.75 $105,506 - $205,959	-6,923 Reduced 18.66%	30,182 $512,000
Q4 2021 Feb 04, 2022	BUY	$25.43 - $34.25 $943,580 - $1.27 Million	37,105 New	37,105 $1.01 Million

154

70M

26.7K

28.6K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $576M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.